192 related articles for article (PubMed ID: 16640121)
1. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia.
Marder SR
Dialogues Clin Neurosci; 2006; 8(1):109-13. PubMed ID: 16640121
[TBL] [Abstract][Full Text] [Related]
2. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.
Marder SR; Fenton W
Schizophr Res; 2004 Dec; 72(1):5-9. PubMed ID: 15531402
[TBL] [Abstract][Full Text] [Related]
3. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
Buchanan RW; Davis M; Goff D; Green MF; Keefe RS; Leon AC; Nuechterlein KH; Laughren T; Levin R; Stover E; Fenton W; Marder SR
Schizophr Bull; 2005 Jan; 31(1):5-19. PubMed ID: 15888422
[TBL] [Abstract][Full Text] [Related]
4. A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project.
Bromley E
Schizophr Bull; 2005 Oct; 31(4):954-61. PubMed ID: 16166607
[TBL] [Abstract][Full Text] [Related]
5. Drug initiatives to improve cognitive function.
Marder SR
J Clin Psychiatry; 2006; 67 Suppl 9():31-5; discussion 36-42. PubMed ID: 16965187
[TBL] [Abstract][Full Text] [Related]
6. New paradigms for treatment development.
Stover EL; Brady L; Marder SR
Schizophr Bull; 2007 Sep; 33(5):1093-9. PubMed ID: 17673495
[TBL] [Abstract][Full Text] [Related]
7. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
8. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Buchanan RW; Keefe RS; Umbricht D; Green MF; Laughren T; Marder SR
Schizophr Bull; 2011 Nov; 37(6):1209-17. PubMed ID: 20410237
[TBL] [Abstract][Full Text] [Related]
9. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
Cohen JD; Insel TR
Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873
[No Abstract] [Full Text] [Related]
10. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
Carter CS; Barch DM; Buchanan RW; Bullmore E; Krystal JH; Cohen J; Geyer M; Green M; Nuechterlein KH; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T; Heinssen R
Biol Psychiatry; 2008 Jul; 64(1):4-10. PubMed ID: 18466880
[TBL] [Abstract][Full Text] [Related]
11. Stimulating the development of drug treatments to improve cognition in schizophrenia.
Green MF
Annu Rev Clin Psychol; 2007; 3():159-80. PubMed ID: 17716052
[TBL] [Abstract][Full Text] [Related]
12. Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective.
Fenton WS; Stover EL; Insel TR
Psychopharmacology (Berl); 2003 Sep; 169(3-4):365-6. PubMed ID: 12955292
[No Abstract] [Full Text] [Related]
13. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.
Buchanan RW; Freedman R; Javitt DC; Abi-Dargham A; Lieberman JA
Schizophr Bull; 2007 Sep; 33(5):1120-30. PubMed ID: 17641146
[TBL] [Abstract][Full Text] [Related]
14. The MATRICS consensus cognitive battery: what we know 6 years later.
Green MF; Harris JG; Nuechterlein KH
Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
[No Abstract] [Full Text] [Related]
15. Methodological issues in negative symptom trials.
Marder SR; Daniel DG; Alphs L; Awad AG; Keefe RS
Schizophr Bull; 2011 Mar; 37(2):250-4. PubMed ID: 21270473
[TBL] [Abstract][Full Text] [Related]
16. The MATRICS initiative: developing a consensus cognitive battery for clinical trials.
Green MF; Nuechterlein KH
Schizophr Res; 2004 Dec; 72(1):1-3. PubMed ID: 15531401
[No Abstract] [Full Text] [Related]
17. Wayne Fenton's impact on industry.
Breier A; Alphs L; Binneman B
Schizophr Bull; 2007 Sep; 33(5):1154-5. PubMed ID: 17562696
[No Abstract] [Full Text] [Related]
18. Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative.
Marder SR; Fenton W; Youens K
Am J Psychiatry; 2004 Jan; 161(1):25. PubMed ID: 14702244
[No Abstract] [Full Text] [Related]
19. Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia.
Cho RY; Ford JM; Krystal JH; Laruelle M; Cuthbert B; Carter CS
Schizophr Bull; 2005 Oct; 31(4):865-9. PubMed ID: 16166611
[TBL] [Abstract][Full Text] [Related]
20. The NIMH-MATRICS consensus statement on negative symptoms.
Kirkpatrick B; Fenton WS; Carpenter WT; Marder SR
Schizophr Bull; 2006 Apr; 32(2):214-9. PubMed ID: 16481659
[No Abstract] [Full Text] [Related]
[Next] [New Search]